Global Melphalan Market Size, Status and Forecast 2021-2028
amiFebruary 13, 2021 36
Melphalan is a medication which can be given as an injection through a vein and is also available in tablet form. The drug comes as a white tablet which is taken while the stomach is empty and the tablets needs to be stored in a cool place. The duration of therapy depends on the types of medications patients take, how well the body reacts to them, and the type of cancer the patient is having. The drug is majorly used for cancer treatment but the physicians also prescribe the drug for treatment of other diseases. The amount of drug to be prescribed depends on various factors such as height and weight of the patient and also considers general health problems of the patient. Presently Melphalan is available in the United States market in the form of capsules as well as injection. There are many suppliers as well as distributors currently active in the market. The Melphalan drug manufacturing compani
Peripheral T-cell Lymphoma Market to exhibit a CAGR of 9.46% during the forecast period of 2020-2030, announces DelveInsight
LAS VEGAS, Feb. 2, 2021 /PRNewswire/ DelveInsight s
Peripheral T-Cell Lymphoma (PTCL) Market report provides an absolute comprehension of the PTCL, historical and forecasted epidemiology and the Peripheral T-Cell Lymphoma market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Peripheral T-Cell Lymphoma market report also proffers an analysis of recent Peripheral T-Cell Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs.
Some of the essential highlights of the
Peripheral T-Cell Lymphoma Market Research Report
Dec 31, 2020 2:00pm An artificial-intelligence-based drug screening effort identified the lymphoma chemotherapy Folotyn (pralatrexate) as a potential treatment for COVID-19. (MF3d/Getty Images)
During a public health emergency, repurposing existing medicines is considered to be a fast route to potential cures, so several companies and academic groups have spent much of the last year looking for COVID-19 remedies in already marketed drugs. Now, a research team from China has identified an approved chemotherapy drug as a potential coronavirus treatment.
By using a combination of computational screening tools, scientists at the Chinese Academy of Sciences’ Shenzhen Institutes of Advanced Technology (SIAT) showed that Acrotech Biopharma’s Folotyn (pralatrexate), a chemotherapy originally developed to treat lymphoma, could be a potent remedy against SARS-CoV-2, the novel coronavirus behind COVID-19.